JAMA NetworkDoes Metformin Improve Outcomes in Nondiabetic, Unresectable Stage III NSCLC Treated with Chemoradiation?

Publication: JAMA Oncology

Objective: With NSCLC having relatively poor outcomes and the significant data supporting the use of metformin as an antineoplastic agent, the researchers wanted to compare overall or progression-free survival in chemoradiation alone vs. chemoradiation + metformin stage III NSCLC patients.

Design: Randomized clinical trial, open-label, phase 2 study; 167 eligible patients